Literature DB >> 18279497

Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.

Ziva D Cooper1, Margaret Haney.   

Abstract

Awareness of cannabis dependence as a clinically relevant issue has grown in recent years. Clinical and laboratory studies demonstrate that chronic marijuana smokers can experience withdrawal symptoms upon cessation of marijuana smoking and have difficulty abstaining from marijuana use. This paper will review data implicating the cannabinoid CB1 receptor in regulating the behavioral effects of Delta(9)-tetrahydrocannobinol (THC), the primary psychoactive component of cannabis, across a range of species. The behavioral effects that will be discussed include those that directly contribute to the maintenance of chronic marijuana smoking, such as reward, subjective effects, and the positive and negative reinforcing effects of marijuana, THC and synthetic cannabinoids. The role of the CB1 receptor in the development of marijuana dependence and expression of withdrawal will also be discussed. Lastly, treatment options that may alleviate withdrawal symptoms and promote marijuana abstinence will be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18279497      PMCID: PMC2731704          DOI: 10.1111/j.1369-1600.2007.00095.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  101 in total

1.  Marijuana withdrawal among adults seeking treatment for marijuana dependence.

Authors:  A J Budney; P L Novy; J R Hughes
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

2.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

3.  The pharmacological activity of inhalation exposure to marijuana smoke in mice.

Authors:  A H Lichtman; J L Poklis; A Poklis; D M Wilson; B R Martin
Journal:  Drug Alcohol Depend       Date:  2001-07-01       Impact factor: 4.492

4.  Cannabinoid receptors and reward in the rat: a conditioned place preference study.

Authors:  J F Cheer; D A Kendall; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  2000-07       Impact factor: 4.530

5.  A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.

Authors:  E Valjent; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

6.  Factors influencing marijuana self-administration by humans.

Authors:  M Haney; S D Comer; A S Ward; R W Foltin; M W Fischman
Journal:  Behav Pharmacol       Date:  1997-06       Impact factor: 2.293

7.  The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study.

Authors:  J M Ng Cheong Ton; G A Gerhardt; M Friedemann; A M Etgen; G M Rose; N S Sharpless; E L Gardner
Journal:  Brain Res       Date:  1988-06-07       Impact factor: 3.252

8.  A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats.

Authors:  Jenny L Wiley; Kari L LaVecchia; Natalie E Karp; Sanjitha Kulasegram; Anu Mahadevan; Raj K Razdan; Billy R Martin
Journal:  Exp Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.157

9.  Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep.

Authors:  Margaret Haney; Erik W Gunderson; Judith Rabkin; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

10.  Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.

Authors:  R S Mansbach; C C Rovetti; E N Winston; J A Lowe
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

View more
  37 in total

Review 1.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  State of the art treatments for cannabis dependence.

Authors:  Itai Danovitch; David A Gorelick
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

3.  Association of Naturalistic Administration of Cannabis Flower and Concentrates With Intoxication and Impairment.

Authors:  L Cinnamon Bidwell; Jarrod M Ellingson; Hollis C Karoly; Sophie L YorkWilliams; Leah N Hitchcock; Brian L Tracy; Jost Klawitter; Cristina Sempio; Angela D Bryan; Kent E Hutchison
Journal:  JAMA Psychiatry       Date:  2020-08-01       Impact factor: 21.596

4.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 5.  Novel medications to treat addictive disorders.

Authors:  Iván D Montoya; Frank Vocci
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

6.  Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze.

Authors:  Peng Huang; Lee-Yuan Liu-Chen; Lynn G Kirby
Journal:  Neurosci Lett       Date:  2010-04-02       Impact factor: 3.046

Review 7.  Cannabis cue-elicited craving and the reward neurocircuitry.

Authors:  Francesca M Filbey; Samuel J DeWitt
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-11-09       Impact factor: 5.067

8.  Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers.

Authors:  Julie A Przybyla; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-12-16       Impact factor: 4.030

Review 9.  Affect and cannabis use in daily life: a review and recommendations for future research.

Authors:  Andrea M Wycoff; Jane Metrik; Timothy J Trull
Journal:  Drug Alcohol Depend       Date:  2018-08-15       Impact factor: 4.492

10.  Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).

Authors:  Claudine C Hunault; Tjeert T Mensinga; Koen B E Böcker; C Maarten A Schipper; Maaike Kruidenier; Marianne E C Leenders; Irma de Vries; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.